Emergent BioSolutions Inc.
First SEC filing: June 3, 2019 · Latest: June 3, 2019
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 1, 2016 | APVO | J | 20,229,849 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-05) |
| Aug. 1, 2016 | APVO | J | 20,230,074 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-05) |
| July 29, 2016 | APVO | J | 20,228,849 | · | · | 20,229,849 Direct | +2022884.90% | Acquired | (price as of 2026-10-05) |
| July 29, 2016 | APVO | J | 20,229,074 | · | · | 20,230,074 Direct | +2022907.40% | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Initial ownership (Form 3) 7 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| June 3, 2019 | EBS | Common Stock | 13,604 | Direct |
| June 3, 2019 | EBS | Stock Options (Right to Buy) | 3,135 | Direct |
| June 3, 2019 | EBS | Stock Options (Right to Buy) | 7,293 | Direct |
| June 3, 2019 | EBS | Stock Options (Right to Buy) | 6,044 | Direct |
| June 3, 2019 | EBS | Stock Options (Right to Buy) | 5,124 | Direct |
| June 3, 2019 | EBS | Stock Options (Right to Buy) | 1,424 | Direct |
| July 15, 2016 | APVO | Common Stock, par value $0.001 per share | 1,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2006 | $369,371 | $116,032 | · | $48,280 | · | · | $32,593 | $566,276 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.